Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient

Julian Thalhammer1,2 • Maria Elena Maccari1,2 • Oliver Wegehaupt1,2 • Stephan Ehl2 • Carsten Speckmann1,2

Received: 22 January 2021 / Accepted: 24 February 2021 / Published online: 29 March 2021
© The Author(s) 2021

To the Editor:

We report on the successful eradication of hepatitis C virus (HCV) by direct-acting antiviral therapy (DAA) with Ledipasvir/Sofosbuvir in an immunodeficient 10-year-old girl with a pathogenic and symptomatic signal transducer and activator of transcription 3 gain of function (STAT3-GOF)-mutation.

The girl was born at term as the second child of non-consanguineous parents in Albania and had recurrent episodes of autoimmune-hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) since the age of 18 months. The initial AIHA/ITP episodes were treated primarily with repeated blood transfusions in her country of origin. Documentation of further initial clinical details including results of Coombs test or auto-antibody screenings remain unknown. At the age of 3 years, she experienced a prolonged episode of AIHA, for which she received multiple transfusions, but also required transient systemic immunosuppressive therapy (IST) with oral steroids. Results of a bone marrow puncture supported the diagnosis of AIHA/ITP. At this time, infectious disease screening identified for the first time an active HCV infection, without quantitative assessment. In the absence of other risk factors, and with her family having tested negative, the infection was most likely related to the previous blood transfusions, a common medical problem in Albania before centralized PCR testing was introduced in 2016 [1].

At the age of 5 years, the family moved to Germany, and, at the age of 7 years, the girl presented to our center with another episode of ITP that had not responded to an intravenous immunoglobulin (IVIG) application (1 g/kg), in the local primary hospital. She displayed mild facial dysmorphic features, i.e., enlarged rotated ears, thin lip vermilion, bilateral epicanthus, squinting, and discrete brachydactyly. Furthermore, mild developmental delay of motor function and speech was recognized. Size (46th percentile) and weight (61st percentile) were normal for her age. Mild splenomegaly was noted on ultrasound, but the patient showed no peripheral lymphadenopathy. Peripheral blood and bone marrow were well compatible with ITP. Molecular cytogenetic evaluation of the bone marrow was without pathological findings. The girl had a positive direct Coombs test, but no active AIHA at this time. There was no history of susceptibility to infections. Immunological studies showed normal IgA and IgM levels. IgG levels and vaccination responses were not informative due to recent IVIG treatment. Immunophenotyping showed normal total lymphocyte and CD3+ T cell count. Yet naïve CD45RA+ T-cells and naïve B-cells were reduced. Activated CD4+ and CD8+ T-cells and CD21 low B-cells were expanded and NK-cell numbers were slightly reduced. For full details, see Table S1. Quantitative PCR revealed an HCV load of 4.7 × 10^6 IU/ml (Abbott®). Laboratory and sonographic liver studies showed normal liver function and anatomy.

After repeated, yet again ineffective, IVIG administrations (3 × 1 g/kg), oral steroid therapy (prednisone 2 mg/kg/d) induced remission of ITP (Fig. 1). An inborn error of immunity (IEI) was assumed in the context of chronic bilinear autoimmune cytopenia, splenomegaly, and dysmorphic features. She was enrolled in our center’s AL-PID study and a genetic diagnosis of germline STAT3-GOF (c.373C>G; p.Gln125Glu) was established by whole exome sequencing and analysis on a panel of 230 known IEI genes. A 17-year-old brother is clinically healthy. After genetic counseling, the family decided against mutation analysis of further family members. The patient’s missense mutation leads to increased transcription of STAT3 but does not change phosphorylation (data not shown) and was observed in another patient of our cohort and functionally analyzed within our AL-PID study [2].
STAT3-GOF (OMIM #15952) is an EII activating signal transduction and thus leading to often early-onset multi-organ autoimmunity. The phenotype and penetrance are highly variable. Eighty-three percent of patients have hematologic involvement, mostly in the form of autoimmune cytopenia and often in combination (57% ITP, 45% AIHA, 21% autoimmune neutropenia) [2]. STAT3-GOF causes pathological lymphoproliferation in around two-thirds of patients.

Susceptibility to mostly respiratory infections is present in half of the patients. Hypogammaglobulinemia (42%) and changes in T-, B-, and NK-cell number and differentiation are common [3].

Six months after the genetic diagnosis at the age of 8 years, the patient had a first life-threatening episode of AIHA with a minimal Hb of 3.4 g/dl despite transfusion of 15 packed red blood cells (PRBCS) over 3 weeks. Initial therapy with oral prednisone 2 mg/kg/day was not successful, yet 3 doses of weekly rituximab (375 mg/m²) led to remission (Fig. 1).

The combination of aggravating autoimmune cytopenia, requiring repeated IST in a STAT3-GOF patient with potentially further decreasing T-cellular immunity over time, raised our concerns about the long-term control of the patient’s chronically active HCV infection. In addition, chronically active virus diseases are contraindications for certain 2nd and 3rd line treatment strategies in severely symptomatic STAT3-GOF patients, i.e., broader immunosuppression by JAK-inhibitors (Jakinibs) or hematopoietic stem cell transplantation (HSCT). Genotyping of HCV revealed genotype 1B in our patient, for which treatment options changed dramatically over the last years. Ledipasvir/Sofosbuvir induces sustained viral responses and received initial approval for adults in the USA in 2014 [4]. Ledipasvir/Sofosbuvir is a combination of a nucleotide analogue inhibitor of the HCV NS5B polymerase and a HCV NS5A inhibitor, which directly act against the HCV. In 2018, Murray et al. reported well-tolerated and effective direct antiviral therapy with Ledipasvir/Sofosbuvir in otherwise healthy children >6 years of age [5]. In February 2019, our patient started an oral DAA off-label treatment with 45/200 mg Ledipasvir/Sofosbuvir once daily at a viral load of 10⁶ IU/ml. After 28 days of DAA therapy, viral load dropped to 30 IU/ml and remained borderline positive after 12 weeks, which is the standard treatment interval for Ledipasvir/Sofosbuvir (Fig. 1). Due to residual viral replication, we extended DAA therapy for another 12 weeks. No clinical or laboratory side effects were observed, yet the general clinical course continued to be complicated by flares of ITP, which we attributed to the underlying disease. ITP was successfully treated with repeated IVIG applications to avoid additional IST. After 21 weeks of antiviral treatment, HCV PCR turned negative for the first time. After completion of a 24-week cycle of Ledipasvir/Sofosbuvir, oral steroids had to be re-administered for recurrent ITP. Immunomodulatory therapy was changed to oral mycophenolate mofetil (1200 mg/m²/day) during steroid taper. One year later, no further cytopenia occurred and the patient remains negative for replicating HCV, notably despite ongoing IST after the end of DAA.
Recently, in June 2020, Ledipasvir/Sofosbuvir was also approved by the European Medicine Agency for use in otherwise healthy children older than 3 years.

DAA achieves sustained viral responses in almost all adult patients with acquired immunodeficiencies such as human immunodeficiency virus (HIV) or IST after kidney transplantation. Historic cases show a high disease burden and mortality of HCV infection in patients with IIE and data on treatment with DAA of those patients, especially children, are scarce [6]. Overall, we see no major concerns regarding the general safety of Ledipasvir/Sofosbuvir, but like to point out with our report, that successful treatment is even possible in immunocompromised pediatric patients—although prolonged therapy cycles might be necessary. Even challenged by continuous IST, HCV eradication by DAA proved to be permanent in our patient. We therefore encourage the earliest possible evaluation for DAA in HCV-infected children and adults with inborn errors of immunity. DAA might be less effective with progressive exacerbation of the underlying primary or treatment-associated secondary immunodeficiency, resulting in a significant risk for loss of viral control and subsequent development of liver cirrhosis and hepatocellular carcinoma.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10875-021-01011-9.

Author Contribution JT wrote the manuscript of the case report and arranged the figures.
CS wrote the manuscript and designed the study, and CS, JT, ME, OW, and SE provide ongoing clinical care for the patient.
CS, ME, OW, and SE contributed to manuscript revision.
All authors approved the final version.

Funding Open Access funding enabled and organized by Projekt DEAL.
CS’s and S.E.’s investigations were supported by the BMBF grant FSE2018-041 and supported by the Deutsche Forschungsgemeinschaft (DFG) grant EXC-2189 – project number 390939984.

Declarations

Conflict of Interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Durro V, Koraqi A, Saliasi S. Trends in the prevalence of transfusion-transmissible infections among blood donors in Albania. Clin Lab. 2010;56(11–12):591–5.
2. Jägle S, Heeg M, Grün S, Rensing-Ehl A, Maccari ME, Kleemann C, et al. Distinct molecular response patterns of activating STAT3 mutations associate with penetrance of lymphoproliferation and autoimmunity. Clin Immunol (Orlando, Fla.). 2020;210:108316. https://doi.org/10.1016/j.clim.2019.108316.
3. Fabre A, Marchal S, Barlogis V, Mari B, Barbry P, Rohrlch P,S, et al. Clinical aspects of STAT3 gain-of-function germline mutations: a systematic review. J Allergy Clin Immunol Pract. 2019;7:1958–1969.e9. https://doi.org/10.1016/j.jaip.2019.02.018.
4. Lawitz E, Poodad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–23. https://doi.org/10.1016/S0140-6736(13)62121-2.
5. Murray KF, Balisteri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, et al. Safety and efficacy of Ledipasvir-Sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6–11. Hepatology. 2018;68:2158–66. https://doi.org/10.1002/hep.30123.
6. Jones TPW. Buckland M, Breuer J, Lowe DM. Viral infection in primary antibody deficiency syndromes. Rev Med Virol. 2019: e2049. https://doi.org/10.1002/rmv.e2049.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.